



## Investor fact sheet

November 2011

### Futura Medical plc

Surrey Technology Centre  
40 Occam Road  
The Surrey Research Park  
Guildford, Surrey, GU2 7YG

Tel: 01483 685670  
info@futuramedical.com  
www.futuramedical.com

### Management

**Chairman** Dr Bill Potter  
**Chief Executive** James Barder  
**Chief Development Officer**  
David Davies  
**Finance Director** Derek Martin

### Share statistics (as at close 28 November 2011)

Share price (p) 62.5p  
Shares in issue (m): 73.08  
Market cap (£m): 45.94  
Year end: 31 December

**Sector:** Pharmaceuticals

**Activities:** Innovative products  
for consumer health  
**Broker/NOMAD:** Nomura Code  
Securities Limited

### Company overview

Futura Medical plc is a pharmaceutical group that develops innovative products for the consumer healthcare market. Futura's shares trade on AIM. We have six products in our development pipeline for sexual healthcare and pain relief management: CSD500, PET500, MED2002, TPR100, TPR100-Rx and RAD100 (see next page). We are evaluating further product opportunities utilising our DermaSys<sup>®</sup> technology.

### Strategy

- **Return on Investment:** we focus on consumer healthcare products that offer the potential for a significant return on the costs of development.
- **Product Profile:** We only incorporate existing chemical entities into our products which gives our development activities a lower risk profile.
- **Over The Counter ("OTC"):** our aim is to produce safe and effective OTC products made available to consumers on a general retail basis or through chemists without the need for a doctor's prescription.
- **Strong Intellectual Property:** the products are underpinned by our developing and retaining valuable intellectual property including know-how, patents and trademarks to protect their commercial position.
- **Licensing:** we aim to out-license our products during their development to established pharmaceutical and healthcare groups which offer the best potential commercial opportunities.

### Partnerships

Futura currently has worldwide agreements covering development and distribution for four of its products with:

### Ansell Ltd

PET500

### GlaxoSmithKline plc

TPR100

### Reckitt Benckiser Group plc

CSD500 and MED2002

### Top shareholders - October 2011

RA Lamb	7.3%
WT Lamb Investments	6.2%
CJ Crabtree	6.2%
Medinvest	5.6%
BlackRock Investment Management (UK) Ltd	5.2%

### Key financial data

	Year ended 31 Dec 10 (£'000)	Year ended 31 Dec 09 (£'000)	Year ended 31 Dec 08 (£'000)
Revenue/Income	125	80	224
R&D	(761)	(810)	(1,391)
Other administrative costs	(700)	(796)	(1,008)
Operating loss	(1,336)	(1,526)	(2,175)
Finance income	19	14	97
Tax credit receivable	226	119	143
Loss after tax	(1,091)	(1,393)	(1,935)
Net cash	825	1,789	782

## Recent news flow

22 November 2011: Block Listing Update  
01 November 2011: Appointment of Non-Executive Chairman  
12 October 2011: Directors' Long Term Incentive Scheme  
04 October 2011: Total Voting Rights  
04 October 2011: Total Voting Rights  
04 October 2011: Holding(s) in Company  
28 September 2011: Grant of Options

## 6 month share price performance



## Product pipeline

### Sexual healthcare

Concept Commercialisation

#### CSD500

Launch planning

CSD500 is a CE marked condom that incorporates an erectogenic compound which comes into contact with the penis on application of the condom.

#### PET500

EU Next milestone: Pivotal clinical trial

USA Launch planning

PET500 is a spray for men with premature ejaculation. It contains anaesthetic compounds which reduce sensitivity to help prolong sexual intercourse.

Delivered by

#### MED2002

Next milestone: Pivotal clinical trial

MED2002 is a topical gel applied directly to the penis for the treatment of male erectile dysfunction. It is expected to be the first OTC treatment for men with erectile dysfunction.

Delivered by

### Pain relief management

#### TPR100

Next milestone: Ongoing development

TPR100 is a product for the provision of topical pain relief. Early clinical work has shown superiority in terms of skin penetration of the active compound compared with the market-leading product.

Delivered by

#### TPR100-Rx

Next milestone: Early stage clinical trial

TPR100-Rx will be a higher strength topical product available on prescription for the treatment of profound indications such as pain associated with osteoarthritis.

Delivered by

#### RAD100

Next milestone: Early stage clinical trial

RAD100 will be a product which aims to provide rapid local anaesthesia prior to injection, vaccination or cannulation.

Delivered by

### Early stage product development

New concepts under evaluation

## Buchanan Communications

Mark Court

markc@buchanan.uk.com

Telephone: +44 (0)20 7466 5000

## Futura Medical plc

James Barder, Chief Executive

james.barder@futura-medical.com

Telephone: +44 (0)1483 685 670

